Use of bacteriophages in the treatment of Pseudomonas aeruginosa infections

References

• Alkawash MA, Soothill JS, Schiller NL. Alginate lyase enhances antibiotic killing of mucoid Pseudomonas aeruginosa in biofilms. APMIS 114, 131–138 (2006).
   PubMed Web of Science ®Google Scholar
• Twort F. An investigation of ultra-microscopic viruses. Lancet 2, 1241–1243 (1915).
   Google Scholar
• D’Herelle F. [On an invisible microbe antagonistic to dysentery bacilli.] Comptes. Rendus. Acad. Sci. 165, 373–375 (1917).
   Google Scholar
• Asheshov IN, Wilson J, Topley WWC. The effect of an anti-vi bacteriophage on typhoid infection in mice. Lancet 1, 319–320 (1937).
   Google Scholar
• Boyd JSK, Portnoy B. Bacteriophage therapy in bacillary dysentery. Trans R. Soc. Trop. Med. Hyg. 37, 243–262 (1944).
   Google Scholar
• Soothill JS. Use of Bacteriophage in the Treatment of Infections. MD thesis. University of London, (1993).
   Google Scholar
• Dubos RJ, Hookey Straus J, Pierce C. The multiplication of bacteriophage in vivo and its protective effect against an experimental infection with Shigella dysenteriae. J. Exp. Med. 78, 161–168 (1943).
   PubMedGoogle Scholar
• Smith HW, Huggins MB. Successful treatment of experimental Escherichia coli infections in mice using phage: its general superiority over antibiotics. J. Gen. Microbiol. 128, 307–318 (1982).
   PubMedGoogle Scholar
• Smith HW, Huggins MB. Effectiveness of phages in treating experimental Escherichia coli diarrhoea in calves, piglets and lambs. J. Gen. Microbiol. 129, 2659–2675 (1983).
   PubMedGoogle Scholar
• Bertoye A, Gaillard L, Courtieu AL. Adapted bacteriophages in the treatment of infections caused by antibiotic-resistant microorganisms. J. Med. Lyon 40, 465–471 (1959).
   PubMedGoogle Scholar
• Bertoye A, Courtieu AL. Treatment of infections caused by pyocyanic bacilli with bacteriophages adapted by selection. J. Med. Lyon 41, 739–751 (1960).
   PubMedGoogle Scholar
• Witoszka M, Strumillo B. Attempted treatment of infected wounds with bacteriophage. Pol. Przegl. Chir. 35, 1054–1056 (1963).
   PubMedGoogle Scholar
• Slopek S, Durlakowa I, Weber-Dabrowska B, Kucharewicz-Krukowska A, Dabrowski M, Bisikiewicz R. Results of bacteriophage treatment of suppurative bacterial infections. II. Detailed evaluation of the results. Arch. Immunol. Ther. Exp. (Warsz) 31, 293–327 (1983).
   PubMed Web of Science ®Google Scholar
• Slopek S, Kucharewicz-Krukowska A, Weber-Dabrowska B, Dabrowski M. Results of bacteriophage treatment of suppurative bacterial infections. IV. Evaluation of the results obtained in 370 cases. Arch. Immunol. Ther. Exp. (Warsz) 33, 219–240 (1985).
   PubMed Web of Science ®Google Scholar
• Hassan HS, El-Tahan A, Massoud B, Gomaa R. Bacteriophage therapy of pseudomonas burn wound sepsis. Ann. Medit. Burn Club 3, 262–264 (1990).
   Google Scholar
• Kochetkova VA, Mamontov AS, Moskovtseva RL et al. Phagotherapy of postoperative suppurative-inflammatory complications in patients with neoplasms. Sov. Med. 6, 23–26 (1989).
   PubMedGoogle Scholar
• Perepanova TS, Darbeeva OS, Kotliarova GA et al. The efficacy of bacteriophage preparations in treating inflammatory urologic diseases. Urol. Nefrol. (Mosk). 5, 14–17 (1995).
   PubMedGoogle Scholar
• Soothill JS, Lawrence JC, Ayliffe GAJ. The efficacy of phages in the prevention of the destruction of pig skin in vitro by Pseudomonas aeruginosa. Med. Sci. Res. 16, 1287–1288 (1988).
   Google Scholar
• Soothill JS. Bacteriophage prevents destruction of skin grafts by Pseudomonas aeruginosa. Burns 20, 209–211 (1994).
   PubMed Web of Science ®Google Scholar
• Soothill JS. Treatment of experimental infections of mice using bacteriophages. J. Med. Microbiol. 37, 258–261 (1992).
   PubMed Web of Science ®Google Scholar
• Soothill JS, Morton DB, Ahmad A. The HID50 (Hypothermia Inducing Dose 50): an alternative to the LD50 for measurement of bacterial virulence. Int. J. Exp. Pathol. 73, 95–98 (1992).
   PubMedGoogle Scholar
• Wang J, Hu B, Xu M, et al. Use of bacteriophage in the treatment of experimental animal bacteremia from imipenem-resistant Pseudomonas aeruginosa. Int. J. Mol. Med. 17, 309–317 (2006).
   PubMed Web of Science ®Google Scholar
• Vinodkumar CS, Kalsurmath S, Neelagund YF. Utility of lytic bacteriophage in the treatment of multidrug-resistant Pseudomonas aeruginosa septicemia in mice. Indian J. Pathol. Microbiol. 51, 360–366 (2008).
   PubMed Web of Science ®Google Scholar
• Heo YJ, Lee YR, Jung HH, Lee J, Ko G, Cho YH. Antibacterial efficacy of phages against Pseudomonas aeruginosa infections in mice and Drosophila melanogaster. Antimicrob. Agents Chemother. 53, 2469–2474 (2009).
   PubMed Web of Science ®Google Scholar
• Tiwari BR, Kim S, Rahman M, Kim J. Antibacterial efficacy of lytic Pseudomonas bacteriophage in normal and neutropenic mice models. J. Microbiol. 49, 994–999 (2011).
   PubMed Web of Science ®Google Scholar
• Watanabe R, Matsumoto T, Sano G et al. Efficacy of bacteriophage therapy against gut-derived sepsis caused by Pseudomonas aeruginosa in mice. Antimicrob. Agents Chemother. 51, 446–452 (2007).
   PubMed Web of Science ®Google Scholar
• Mc Vay CS, Velásquez M, Fralick JA. Phage therapy of Pseudomonas aeruginosa infection in a mouse burn wound model. Antimicrob. Agents Chemother. 51, 1934–1938. (2007).
   PubMedGoogle Scholar
• Hall AR, De Vos D, Friman VP, Pirnay JP, Buckling A. Effects of sequential and simultaneous applications of bacteriophages on populations of Pseudomonas aeruginosa in vitro and in wax moth larvae. Appl. Environ. Microbiol. 78, 5646–5652 (2012).
   PubMed Web of Science ®Google Scholar
• Debarbieux L, Leduc D, Maura D et al. Bacteriophages can treat and prevent Pseudomonas aeruginosa lung infections. J. Infect. Dis. 201, 1096–1104 (2010).
   PubMed Web of Science ®Google Scholar
• Morello E, Saussereau E, Maura D, Huerre M, Touqui L, Debarbieux L. Pulmonary bacteriophage therapy on Pseudomonas aeruginosa cystic fibrosis strains: first steps towards treatment and prevention. PLoS ONE 6, e1 6963. (2011).
   Google Scholar
• Alemayehu D, Casey PG, McAuliffe O et al. Bacteriophages φMR299–2 and φNH-4 can eliminate Pseudomonas aeruginosa in the murine lung and on cystic fibrosis lung airway cells. MBio 3(2), e00029-e00012 (2012).
   PubMed Web of Science ®Google Scholar
• Hagens S, Habel A, Von Ahsen U, Von Gabain A, Bläsi U. Therapy of experimental Pseudomonas infections with a nonreplicating genetically modified phage. Antimicrob. Agents Chemother. 48, 3817–3822 (2004).
   PubMed Web of Science ®Google Scholar
• Marza JA, Soothill JS, Boydell P, Collyns TA. Multiplication of therapeutically administered bacteriophages in Pseudomonas aeruginosa infected patients. Burns 32, 644–646 (2006).
   PubMed Web of Science ®Google Scholar
• Hawkins C, Harper D, Burch D, Anggård E, Soothill J. Topical treatment of Pseudomonas aeruginosa otitis of dogs with a bacteriophage mixture: A before/after clinical trial. Vet. Microbiol. 15, 309–313 (2010).
   Google Scholar
• Wright A, Hawkins CH, Anggård EE, Harper DR. A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy. Clin. Otolaryngol. 34, 349–357 (2009).
   PubMed Web of Science ®Google Scholar
• Weber-Dabrowska B, Dabrowski M, Slopek S. Studies on bacteriophage penetration in patients subjected to phage therapy. Arch. Immunol. Ther. Exp. (Warsz) 35, 563–568 (1987).
   PubMed Web of Science ®Google Scholar
• Hildebrand GJ, Wolochow H. Translocation of bacteriophage across the intestinal wall of the rat. Proc. Soc. Exp. Biol. Med. 109, 183–185 (1962).
   PubMed Web of Science ®Google Scholar
• Park BH. An enzyme produced by a phage-host cell system. I. The properties of a Klebsiella phage.Virology 2, 711–718 (1956).
   PubMedGoogle Scholar
• Bartell PF, Lam GK, Orr TE. Purification and properties of polysaccharide depolymerase associated with phage-infected Pseudomonas aeruginosa. J. Biol. Chem. 10(243), 2077–2080 (1968).
   Google Scholar
• Ghani M. The Effect of Antibiotics and Bacteriophages on Biofilms of Pseudomonas Aeruginosa. PhD Thesis. University of Manchester, UK (1996).
   Google Scholar
• Hanlon GW, Denyer SP, Olliff CJ, Ibrahim LJ. Reduction in exopolysaccharide viscosity as an aid to bacteriophage penetration through Pseudomonas aeruginosa biofilms. Appl. Environ. Microbiol. 67, 2746–2753 (2001).
   PubMed Web of Science ®Google Scholar
• Glonti T, Chanishvili N, Taylor PW. Bacteriophage-derived enzyme that depolymerizes the alginic acid capsule associated with cystic fibrosis isolates of Pseudomonas aeruginosa. J. Appl. Microbiol. 108, 695–702 (2010).
   PubMed Web of Science ®Google Scholar
• Bayer AS, Park S, Ramos MC, Nast CC, Eftekhar F, Schiller NL. Effects of alginase on the natural history and antibiotic therapy of experimental endocarditis caused by mucoid Pseudomonas aeruginosa. Infect. Immun. 60, 3979–3985 (1992).
   PubMed Web of Science ®Google Scholar
• Ghani M, Soothill JS. Rapid, continuous propagation of bacteriophage in biofilms. Infect. Dis. Rev. 1, 30–31 (1999).
   Google Scholar
• Doolittle MM, Cooney JJ, Caldwell DE. Tracing the interaction of bacteriophage with bacterial biofilms using fluorescent and chromogenic probes. J. Ind. Microbiol. 16, 331–341. (1996).
   PubMedGoogle Scholar
• Fu W, Forster T, Mayer O, Curtin JJ, Lehman SM, Donlan RM. Bacteriophage cocktail for the prevention of biofilm formation by Pseudomonas aeruginosa on catheters in an in vitro model system. Antimicrob. Agents Chemother. 54, 397–404 (2010).
   PubMed Web of Science ®Google Scholar
• Kim S, Rahman M, Seol SY, Yoon SS, Kim J. Pseudomonas aeruginosa bacteriophage PA1Ø requires type IV pili for infection and shows broad bactericidal and biofilm removal activities. Appl. Environ. Microbiol. 78, 6380–6385 (2012).
   PubMed Web of Science ®Google Scholar
• Zhang Y, Hu Z. Combined treatment of Pseudomonas aeruginosa biofilms with bacteriophages and chlorine. Biotechnol. Bioeng. 110, 286–295 (2013).
   PubMed Web of Science ®Google Scholar
• Budzik JM, Rosche WA, Rietsch A, O'Toole GA. Isolation and characterization of a generalized transducing phage for Pseudomonas aeruginosa strains PAO1 and PA14. J. Bacteriol. 186, 3270–3273 (2004).
   PubMedGoogle Scholar
• Zegans ME, Wagner JC, Cady KC, Murphy DM, Hammond JH, O'Toole GA. Interaction between bacteriophage DMS3 and host CRISPR region inhibits group behaviors of Pseudomonas aeruginosa. J. Bacteriol. 191, 210–219 (2009).
   PubMed Web of Science ®Google Scholar
• Ochs HD, Davis SD, Wedgwood RJ. Immunologic responses to bacteriophage phi-X 174 in immunodeficiency diseases. J. Clin. Invest. 50, 2559–2568 (1971).
   PubMed Web of Science ®Google Scholar